ProfileGDS5678 / 1437225_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 80% 80% 79% 80% 82% 79% 78% 79% 82% 81% 80% 80% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6535380
GSM967853U87-EV human glioblastoma xenograft - Control 25.7089880
GSM967854U87-EV human glioblastoma xenograft - Control 35.7093280
GSM967855U87-EV human glioblastoma xenograft - Control 45.7213379
GSM967856U87-EV human glioblastoma xenograft - Control 55.6572780
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7418982
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3937679
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.3879178
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4539179
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.9704782
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.7267781
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6865680
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6940280
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.7623481